GlassScriptPhysician profile
Gary S Friedman
NPI 1033170931
$4,776.30
in general payments reported to CMS, 2019-2025
28 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $347 · 2021: $701 · 2022: $258 · 2023: $769 · 2024: $787 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $721.31 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $513.89 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $505.31 | 2021-2025 | Xcopri |
| Amgen INC. | $419.91 | 2019-2025 | Uplizna |
| Ucb, INC. | $410.08 | 2019-2024 | Briviact |
| Genzyme Corporation | $400.52 | 2019-2021 | |
| Biogen, INC. | $359.86 | 2019-2025 | Leqembi |
| Pfizer INC. | $248.54 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $213.41 | 2020-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $155.35 | 2020-2021 | |
| Akcea Therapeutics, INC. | $125.00 | 2020 | |
| Genentech USA, INC. | $111.46 | 2022 | |
| Neurocrine Biosciences, INC. | $106.10 | 2019-2025 | Ingrezza |
| Lilly USA, LLC | $75.02 | 2020-2023 | Amyvid |
| Argenx US, INC. | $73.61 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66.43 | 2025 | |
| Janssen Biotech, INC. | $42.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.38 | 2019-2025 | Camzyos |
| Invivyd INC | $30.09 | 2025 | Pemgarda |
| Medtronic, INC. | $23.17 | 2021 | |
| Abbott Laboratories | $20.49 | 2025 | Infinity |
| Celgene Corporation | $19.55 | 2021 | |
| Owp Pharmaceuticals, INC. | $18.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.36 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $16.71 | 2020 | |
| Medtronic USA, INC. | $16.31 | 2020 | |
| Horizon Therapeutics Plc | $14.97 | 2023 | Uplizna |
| Grifols USA, LLC | $13.10 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.